Toxicology Related Antibodies


Toxicology Overview

 

Toxicology can be defined as the study of adverse effects of chemical and physical substances in living organisms. Toxicology plays a critical role in the process of drug development, determining potential adverse drug reactions during preclinical and clinical studies and also in post-marketing studies evaluating the risk–benefit ratio of approved medicines. Toxicity studies of drug candidates are commonly based on the detection, measurement and evaluation of protein biomarkers.

 

 

Antibodies and Immunoassays for Toxicology

 

Rockland Immunochemicals catalog portfolio includes exclusive monoclonal and polyclonal antibodies that bind to biomarkers crucial for toxicology research needs in the areas of cell signaling, cellular metabolism, epigenetics, immunology and inflammation, neuroscience, cardiovascular and cancer drug discovery.

 

Additional toxicology immunoassay kits offered by Rockland include CellCountEZ®, OxPhosTM, RadDoseTM and the Intracellular ThiolEZTM assays, well established technologies developed by LIMR Development, Inc. (LDI), the business subsidiary of Lankenau Institute for Medical Research (LIMR).   

Rockland’s cell viability assaysand BrdU detection antibodies are ideal for determination of proliferation, cell cycle, or cell survival, based on a total cell population. Cell viability assesses healthy cells in a sample, with no distinction between dividing or quiescent cells. An increase in cell viability indicates cell growth, while a decrease in viability can generally be interpreted as the result of either toxic effects of compounds/agents or suboptimal culture conditions.  

 

 

Featured Toxicology Assays and Antibodies

 

 anti-IDO2      

200301E61  

   

  anti-brdU

Anti-IDO2 (RABBIT)

 

600-401-C69

 

Anti-BIN1 (MOUSE) Monoclonal

 

200-301-E61

 

Anti-BrdU

 

600-401-C29

Cell Viability Assays

 

Camilo Moncada, Ph.D. is a senior scientist and Director of QC at Rockland Immunochemicals, a leading company in antibody development. Dr. Moncada began his research studies more than 10 years ago and because of his active participation in a number of projects, he has joint publications in different subjects including immunology, parasitology, cancer and lung disease. At Rockland, he applies his expertise on molecular and cellular biology, biochemistry and proteomics for antibody development and validation.

 

 

 

 


 

 
 

 

 
Rockland collaborates with LIMR to provide monoclonal and polyclonal antibodies, which bind biomarkers crucial for cell signaling, immune system regulation, inflammatory responses, cellular metabolism, and cancer progression.